{"id":7974,"date":"2025-09-27T19:47:35","date_gmt":"2025-09-27T19:47:35","guid":{"rendered":"https:\/\/polikistikover.net\/yeni\/?page_id=7974"},"modified":"2025-11-16T22:37:18","modified_gmt":"2025-11-16T22:37:18","slug":"polikistik-over-sendromunda-cinsel-istek-ve-escinsellik-lezbiyen-gay-transseksuel","status":"publish","type":"page","link":"https:\/\/polikistikover.net\/yeni\/polikistik-over-sendromunda-cinsel-istek-ve-escinsellik-lezbiyen-gay-transseksuel\/","title":{"rendered":"Polikistik Over Sendromu\u2019nda Cinsel \u0130stek ve E\u015fcinsellik (Lezbiyen, Gay, Transseks\u00fcel)"},"content":{"rendered":"\n

Polikistik Over Sendromu\u2019nda cinsel iste\u011fi erkeklik hormonlar\u0131 (testosteron, dihidrotestosteron) ve \u00f6strojen (estradiol) hormonu belirlemektedir(5).<\/mark><\/strong><\/p>\n\n\n\n

Beyinde bulunan cinsel istek al\u0131c\u0131lar\u0131 (resept\u00f6r) testosteron taraf\u0131ndan uyar\u0131lmaktad\u0131r(6).<\/mark><\/strong><\/p>\n\n\n\n

1-<\/mark><\/strong>Polikistik Over Sendromu olan kad\u0131nlar\u0131n bir k\u0131sm\u0131nda erkeklik hormonlar\u0131 fazla miktarda \u00fcretilmektedir. Bir k\u0131sm\u0131nda ise erkeklik hormonu miktar\u0131 normal olmas\u0131na ra\u011fmen ba\u011flanarak onlar\u0131 etkisiz hale getiren madde olan Sex Hormone Binding Globulin (SHBG) daha az miktarda \u00fcretilmektedir.<\/p>\n\n\n\n

2-<\/mark><\/strong>SHBG miktar\u0131n\u0131n az olmas\u0131 erkeklik hormonu miktar\u0131n\u0131n normal seviyede olmas\u0131na ra\u011fmen serbest dola\u015fan yani ba\u011flanmam\u0131\u015f olan erkeklik hormonlar\u0131n\u0131n (serbest testosteron) miktar ve etkinli\u011finin artmas\u0131na neden olmaktad\u0131r(6,7).<\/p>\n\n\n\n

3-<\/mark><\/strong>SHBG ye ba\u011flanmam\u0131\u015f testosteron erkeklik hormonlar\u0131n\u0131n en etkili formu olan dihidrotestosteron (DHT) hormonuna d\u00f6n\u00fc\u015fmektedir.<\/p>\n\n\n\n

4-<\/mark><\/strong>Cinsel istek (cinsellik) erkeklik hormonlar\u0131 ve onlar\u0131n son \u00fcr\u00fcn\u00fc olan dihidrotestosteron miktar\u0131 ile do\u011fru orant\u0131l\u0131 olarak, SHBG miktar\u0131 ile ters orant\u0131l\u0131 olarak de\u011fi\u015fmektedir(10).<\/p>\n\n\n\n

5-<\/mark><\/strong>Do\u011fum kontrol hap\u0131 kullanan ki\u015filerde yumurtal\u0131klar bask\u0131land\u0131\u011f\u0131 i\u00e7in erkeklik hormonu \u00fcretimi azal\u0131r ve SHBG miktar\u0131 artar. Bunun sonucunda do\u011fum kontrol hap\u0131 kullanan ki\u015filerde zaman i\u00e7inde cinsel isteksizlik ortaya \u00e7\u0131kabilmektedir(8,9).<\/p>\n\n\n\n

6-<\/mark><\/strong>Polikistik over sendromu olsun ya da olmas\u0131n b\u00fct\u00fcn kad\u0131nlarda erkeklik hormonlar\u0131n\u0131n miktarlar\u0131 ya\u015f ilerledik\u00e7e 20 li ya\u015flardan itibaren \u00f6zellikle 40 l\u0131 ya\u015flar\u0131 takiben azalmaktad\u0131r(35). Bunun sonucunda ya\u015f ilerledik\u00e7e zaman i\u00e7inde cinsel isteksizlik ortaya \u00e7\u0131kabilmektedir. Fakat, Polikistik over sendromu\u2019nda erkeklik hormonlar\u0131 polikistik over sendromu olmayan kad\u0131nlara g\u00f6re daha fazla miktarlarda olmaya ileri ya\u015flarda hatta menopoz sonras\u0131nda da devam etmektedir(36,37,38,39,40,41,42).<\/p>\n\n\n\n

<\/p>\n\n\n\n

Polikistik over sendromu olan kad\u0131nlar\u0131n bir k\u0131sm\u0131nda erkeklik hormonlar\u0131n\u0131n fazla miktarda \u00fcretilmesi ve fazla miktarda \u00fcretilen erkeklik hormonlar\u0131n\u0131n da daha fazla miktarda dihidrotestosteron hormonuna d\u00f6n\u00fc\u015fmesi nedeniyle cinsel istek (libido) art\u0131\u015f\u0131 ile birlikte agresif, sald\u0131rgan, gergin, sinirli ve \u00f6fkeli davran\u0131\u015flar\u0131 i\u00e7eren psikolojik sorunlar g\u00f6r\u00fclebilmektedir(1,2,3).<\/mark><\/strong><\/p>\n\n\n\n

Polikistik over sendromu olan kad\u0131nlardan erkeklik hormonlar\u0131 fazla miktarda \u00fcretilenlerde e\u015fcinsel (lezbiyen, gay) olma ihtimalinin polikistik over sendromu olmayan kad\u0131nlardan daha fazla oldu\u011fu g\u00f6r\u00fclmektedir(43,44,45,46).<\/mark><\/strong><\/p>\n\n\n\n

Polikistik over sendromu olan e\u015fcinsel kad\u0131nlar\u0131n bir k\u0131sm\u0131nda daha \u00e7ok k\u0131sa sa\u00e7, erkeksi giyim ve davran\u0131\u015flar\u0131 i\u00e7eren erkek rol\u00fcn\u00fcn (butch) \u00fcstlenildi\u011fi g\u00f6r\u00fclmektedir.<\/mark><\/strong><\/p>\n\n\n\n

 Kad\u0131ndan erke\u011fe cinsiyet de\u011fi\u015fikli\u011fi (female-to-male transsexulas) g\u00f6sterenlerin b\u00fcy\u00fck bir k\u0131sm\u0131nda da erke\u011fe d\u00f6n\u00fc\u015f\u00fcm amac\u0131yla herhangi bir erkeklik hormonu tedavisi kullanmadan, yine erke\u011fe d\u00f6n\u00fc\u015f\u00fcm amac\u0131yla yumurtal\u0131klar (oophorectomy) ve memeler (mastectomy) ameliyat ile \u00e7\u0131kart\u0131lmadan \u00f6nce erkeklik hormonlar\u0131 fazla miktarda \u00fcretilmektedir(43,44,45).<\/mark><\/strong><\/p>\n\n\n\n

Polikistik over sendromu olan normal kilolu veya zay\u0131f ya da fazla kilolu veya \u015fi\u015fman e\u015fcinsel kad\u0131nlar\u0131n bir k\u0131sm\u0131nda kar\u0131n ve bel \u00e7evresinde ya\u011f miktar\u0131 fazla (erkek tipi ya\u011flanma) oldu\u011fu i\u00e7in bel \u00e7evresi kal\u0131nl\u0131\u011f\u0131 g\u00f6r\u00fclmektedir(47,48,49,50,51). <\/p>\n\n\n\n

Polikistik over sendromu olan ve bel \u00e7evresi kal\u0131n kad\u0131nlarda bel \u00e7evresi kal\u0131n olmayan ayn\u0131 kiloya sahip kad\u0131nlara g\u00f6re daha fazla oranda kalp ve damar hastal\u0131\u011f\u0131 ihtimalini artt\u0131ran metabolik sendrom ortaya \u00e7\u0131kmaktad\u0131r(52,53).<\/mark><\/strong><\/p>\n\n\n\n

Polikistik over sendromu\u2019nda fazla kilolu ve \u015fi\u015fman olan veya normal kilolu fakat bel \u00e7evresi kal\u0131n (erkek tipi ya\u011flanma) olan e\u015fcinsel kad\u0131nlar\u0131n b\u00fcy\u00fck \u00e7o\u011funlu\u011funda ins\u00fclin direnci g\u00f6r\u00fclmektedir(45,46).<\/mark><\/strong><\/p>\n\n\n\n

\u0130ns\u00fclin direncinin ilerlemesi, k\u00f6t\u00fcye gitmesi sonucunda bu kad\u0131nlarda bozulmu\u015f glukoz (\u015feker) tolerans\u0131 ve \u015feker hastal\u0131\u011f\u0131 (Diabetes mellitus) geli\u015fmektedir(54,55,56,57,58,59,60).<\/mark><\/strong><\/p>\n\n\n\n

1-<\/mark><\/strong>Erkeklik hormonlar\u0131n\u0131n (testosteron, dihidrotestosteron) b\u00fcy\u00fck bir k\u0131sm\u0131 b\u00f6brek \u00fcst\u00fc bezinde (Adrenal Gland) \u00fcretilen DHEA (Dehydroepiandrosterone) ve Androstenedione hormonlar\u0131n\u0131 hammadde olarak kullanarak k\u0131l k\u00f6kleri ve ya\u011f bezlerinin bulundu\u011fu deri, ya\u011f dokusu ve meme gibi ayn\u0131 zamanda erkeklik hormonlar\u0131n\u0131n (testosteron, dihidrotestosteron) hedefi olan organlarda\u00a0\u00fcretilirken ancak k\u00fc\u00e7\u00fck bir k\u0131sm\u0131 yumurtal\u0131k ve b\u00f6brek \u00fcst\u00fc bezinde \u00fcretilmektedir\u00a0(Intracrinology)(11,12).<\/p>\n\n\n\n

2-<\/mark><\/strong>Kan dola\u015f\u0131m\u0131nda bulunan testosteron miktar\u0131 sadece yumurtal\u0131k ve b\u00f6brek \u00fcst\u00fc bezinden do\u011frudan sal\u0131nan miktar\u0131 g\u00f6stermektedir.<\/p>\n\n\n\n

3-<\/mark><\/strong>Kad\u0131nlarda testosteron hormonunun b\u00fcy\u00fck k\u0131sm\u0131n\u0131n\u00a0\u00fcretildi\u011fi deri, ya\u011f dokusu, meme gibi organlardan ancak k\u00fc\u00e7\u00fck bir miktar (%10) testosteron kan dola\u015f\u0131m\u0131na girmektedir(13).<\/p>\n\n\n\n

4-<\/mark><\/strong>Kan dola\u015f\u0131m\u0131na girmeyen testosteron hormonunun b\u00fcy\u00fck \u00e7o\u011funlu\u011fu ise 5-\u00a0\u03b1 reduktaz (reductase) enzimi taraf\u0131ndan dihidrotestosteron (dhydrotestosterone) hormonuna d\u00f6n\u00fc\u015fmektedir(14,15,16).<\/p>\n\n\n\n

5-<\/mark><\/strong>Dihidrotestosteron hormonu testosteron hormonundan 10 kat daha g\u00fc\u00e7l\u00fc bir etkiye sahiptir(17).<\/p>\n\n\n\n

6-<\/mark><\/strong>Dihidrotestosteron hormonunun da testosteron hormonu gibi b\u00fcy\u00fck \u00e7o\u011funlu\u011fu (%90) kan dola\u015f\u0131m\u0131na girmemektedir(15,18).\u00a0<\/p>\n\n\n\n

7-<\/mark><\/strong>Deri, ya\u011f dokusu, meme gibi organlarda \u00fcretilen\u00a0dihidrotestosteron (DHT)\u00a0hormonunun b\u00fcy\u00fck \u00e7o\u011funlu\u011fu UGT- enzimi ile herhangi bir hormon etkisi olmayan \u00fcr\u00fcnler\u00a0(metabolit) olan 3\u00a0\u03b1- androstanediol glucuronide (3\u03b1 diol G) ve androsterone Glucuronide (ADT-G) d\u00f6n\u00fc\u015ferek deri h\u00fccresinden kan dola\u015f\u0131m\u0131na girmektedir(19,20,21,22).<\/p>\n\n\n\n

Tedavi;<\/strong><\/p>\n\n\n\n

Dihidrotestosteron hormonunun hammaddesi olan erkeklik hormonlar\u0131n\u0131n etkinli\u011finin ve miktar\u0131n\u0131n azalt\u0131lmas\u0131, dihidrotestosteron hormonuna d\u00f6n\u00fc\u015f\u00fcm\u00fcn azalt\u0131lmas\u0131 ve Sex Hormon Binding Globulin miktar\u0131n\u0131n artt\u0131r\u0131lmas\u0131 sonucunda cinsel istek (libido) art\u0131\u015f\u0131 ile birlikte agresif, sald\u0131rgan, gergin, sinirli ve \u00f6fkeli davran\u0131\u015flar\u0131 i\u00e7eren psikolojik sorunlar d\u00fczelebilmektedir. <\/mark><\/strong><\/p>\n\n\n\n

Tedavi Y\u00f6ntemleri;<\/strong><\/p>\n\n\n\n

1-<\/mark><\/strong> \u0130ns\u00fclin direnci olan kad\u0131nlarda ins\u00fclin duyarl\u0131l\u0131\u011f\u0131n\u0131n ila\u00e7 tedavisi ile artt\u0131r\u0131lmas\u0131na ba\u011fl\u0131 olarak kan dola\u015f\u0131m\u0131nda bulunan ins\u00fclin miktar\u0131n\u0131n azalmas\u0131 yumurtal\u0131kta fazla miktarda \u00fcretilen erkeklik hormonlar\u0131n\u0131 (androstenedione, testosteron) azaltmaktad\u0131r(23,24). \u0130ns\u00fclin direncinin azalmas\u0131 ayn\u0131 zamanda karaci\u011ferde \u00fcretilen SHBG miktar\u0131n\u0131 artt\u0131rmakta ve erkeklik hormonlar\u0131n\u0131n serbest dola\u015fan etkin formlar\u0131n\u0131n (serbest testosteron) miktar\u0131n\u0131n azalmas\u0131na neden olmaktad\u0131r(23,24).<\/p>\n\n\n\n

2-<\/mark> Kan dola\u015f\u0131m\u0131nda bulunan erkeklik hormonlar\u0131n\u0131n bir k\u0131sm\u0131 al\u0131c\u0131lara (androgen receptor) tutunarak etki etmektedir. Erkeklik hormonlar\u0131n\u0131n al\u0131c\u0131lara tutunmas\u0131n\u0131n engellenmesi (androgen receptor antagonist) di\u011fer bir tedavi se\u00e7ene\u011fidir(4,25,26,27). Bu ama\u00e7la kullan\u0131lan ila\u00e7lar\u0131n (androgen receptor antagonist) do\u011fum kontrol haplar\u0131 gibi hayati tehlikeye sahip yan etkileri (bacak damarlar\u0131n\u0131n p\u0131ht\u0131 ile t\u0131kanmas\u0131 ve ordan kopan p\u0131ht\u0131 par\u00e7as\u0131n\u0131n da akci\u011fer damarlar\u0131n\u0131 t\u0131kamas\u0131 ve meme kanseri) yoktur(28,29,30).<\/p>\n\n\n\n

3-<\/mark> Al\u0131c\u0131lara (receptor) tutunarak h\u00fccre i\u00e7ine giren testosteron ile h\u00fccrede \u00fcretilen testosteron hormonunun b\u00fcy\u00fck \u00e7o\u011funlu\u011fu 5- \u03b1 reduktaz (reductase) enzimi taraf\u0131ndan dihidrotestosteron (dhydrotestosterone) hormonuna d\u00f6n\u00fc\u015fmektedir(14,15,16).<\/p>\n\n\n\n

 5- \u03b1 reduktaz (reductase) enziminin bu etkisinin engellenmesi (5- \u03b1  reductase inhibitor) de bir tedavi se\u00e7ene\u011fidir(31,32,33). Bu ama\u00e7la kullan\u0131lan ila\u00e7lar\u0131n (5-\u03b1 reductase inhibitor) do\u011fum kontrol haplar\u0131 gibi hayati tehlikeye sahip yan etkileri (bacak damarlar\u0131n\u0131n p\u0131ht\u0131 ile t\u0131kanmas\u0131 ve ordan kopan p\u0131ht\u0131 par\u00e7as\u0131n\u0131n da akci\u011fer damarlar\u0131n\u0131 t\u0131kamas\u0131 ve meme kanseri) yoktur(34).<\/p>\n\n\n\n

4-<\/mark><\/strong> Polikistik over sendromu olan kad\u0131nlarda ya\u015fanan psikolojik sorunlar\u0131n \u00e7\u00f6z\u00fcmlenmesine y\u00f6nelik al\u0131nacak profesyonel bir psikiyatrik yard\u0131m ve polikistik over Sendromu\u2019nun tedavisi birlikte bir b\u00fct\u00fcnl\u00fck olu\u015fturmaktad\u0131r.<\/p>\n\n\n\n

Kaynaklar<\/strong><\/p>\n\n\n\n

1-Risk of psychiatric disorders following polycystic ovary syndrome: a nationwide population-based cohort study. Hung JH, Hu LY, Tsai SJ, Yang AC, Huang MW, Chen PM, Wang SL, Lu T, Shen CC. PLoS One. 2014 May 9;9(5):e97041.<\/p>\n\n\n\n

2-Androgens and mood dysfunction in women: comparison of women with polycystic ovarian syndrome to healthy controls. Weiner CL, Primeau M, Ehrmann DA. Psychosom Med. 2004 May-Jun;66(3):356-62.<\/p>\n\n\n\n

3-Psychological parameters in the reproductive phenotypes of polycystic ovary syndrome. Moran LJ, Deeks AA, Gibson-Helm ME, Teede HJ. Hum Reprod. 2012 Jul;27(7):2082-8.<\/p>\n\n\n\n

4-The role of androgen receptor in skin related disorders. Lai JJ, Chang P, Lai KP, Chen L, Chang C. Arch Dermatol Res. 2012 Sep;304(7):499-510.<\/p>\n\n\n\n

5-Neurosteroids: a novel function of the brain. Baulieu EE Psychoneuroendocrinology. 1998  Nov;23(8):963-87.<\/p>\n\n\n\n

6-Hormone receptors and sexuality in the human female. DeCherney AH. J Womens Health Gend Based Med. 2000;9 Suppl 1:S9-13.<\/p>\n\n\n\n

7-Implications of hormonal influences on sexual behavior for demographic models of reproduction. Campbell BC, Udry JR. Ann N Y Acad Sci. 1994 Feb 18;709:117-27.<\/p>\n\n\n\n

8-Hormonal contraception and sexual desire: A questionnaire-based study of young Swedish women. Malmborg A, Persson E, Brynhildsen J, Hammar M. Eur J Contracept Reprod Health Care. 2016;21(2):158-67.<\/p>\n\n\n\n

9-Oral contraceptives, androgens, and the sexuality of young women: II. The role of androgens. Bancroft J , Sherwin BB, Alexander GM, Davidson DW, Walker A. Arch Sex Behav. 1991  Apr;20(2):121-35.<\/p>\n\n\n\n

10-Controlled studies on women presenting with sexual drive disorder: I. Endocrine status. Riley A, Riley E. J Sex Marital Ther. 2000 Jul-Sep;26(3):269-83.<\/p>\n\n\n\n

11-Intracrinology. Labrie F. Mol Cell Endocrinol. 1991 Jul;78(3):C113-8.<\/p>\n\n\n\n

12-Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Labrie F, Luu-The V, Labrie C, B\u00e9langer A, Simard J, Lin SX, Pelletier G. Endocr Rev. 2003 Apr;24(2):152-82.<\/p>\n\n\n\n

13-DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Labrie F, Luu-The V, Labrie C, Simard J. Front Neuroendocrinol. 2001 Jul;22(3):185-212.<\/p>\n\n\n\n

14-Sexual hormones in human skin. Zouboulis CC, Chen WC, Thornton MJ, Qin K, Rosenfield R. Horm Metab Res. 2007 Feb;39(2):85-95.<\/p>\n\n\n\n

15-Dihydrotestosterone is a peripheral paracrine hormone. Horton R. J Androl. 1992 Jan-Feb;13(1):23-7.<\/p>\n\n\n\n

16-Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. J Clin Invest. 1993 Aug;92(2):903-10.<\/p>\n\n\n\n

17-Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin. Saartok T, Dahlberg E, Gustafsson JA. Endocrinology. 1984 Jun;114(6):2100-6.<\/p>\n\n\n\n

18-Origin of plasma androstanediol glucuronide in men. Moghissi E, Ablan F, Horton R. J Clin Endocrinol Metab. 1984 Sep;59(3):417-21.<\/p>\n\n\n\n

19-Quantitative determination of beta-glucuronidase in sweat gland and other skin components in cystic fibrosis. Gibbs GE, Friffin GD. J Invest Dermatol. 1968 Sep;51(3):200-3.<\/p>\n\n\n\n

20-Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. B\u00e9langer A, Pelletier G, Labrie F, Barbier O, Chouinard S. Trends Endocrinol Metab. 2003 Dec;14(10):473-9.<\/p>\n\n\n\n

21-Inactivation by UDP-glucuronosyltransferase enzymes: the end of androgen signaling. Chouinard S, Yueh MF, Tukey RH, Giton F, Fiet J, Pelletier G, Barbier O, B\u00e9langer A. J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):247-53.<\/p>\n\n\n\n

22-Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. Labrie F, B\u00e9langer A, B\u00e9langer P, B\u00e9rub\u00e9 R, Martel C, Cusan L, Gomez J, Candas B, Castiel I, Chaussade V, Deloche C, Leclaire J. J Steroid Biochem Mol Biol. 2006 Jun;99(4-5):182-8.<\/p>\n\n\n\n

23-Clinical review: Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. Cosma M, Swiglo BA, Flynn DN, Kurtz DM, Labella ML, Mullan RJ, Elamin MB, Erwin PJ, Montori VM. J Clin Endocrinol Metab. 2008 Apr;93(4):1135-42.<\/p>\n\n\n\n

24- Treatment Options for Hirsutism: A Systematic Review and Network Meta- Analysis . Barrionuevo P, Nabhan M, Altayar O, Wang Z, Erwin PJ, Asi N, Martin KA, Murad MH. J Clin Endocrinol Metab. 2018 Apr 1;103(4):1258-1264.<\/p>\n\n\n\n

25-The endocrine effects of spironolactone used as an antiandrogen. Young RL, Goldzieher JW, Elkind-Hirsch K. Fertil Steril. 1987 Aug;48(2):223-8.<\/p>\n\n\n\n

26-A systematic review of commonly used medical treatments for hirsutism in women. Koulouri O, Conway GS. Clin Endocrinol (Oxf). May;68(5):800-5.<\/p>\n\n\n\n

27-Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone F, Caputo M, Muggeo M, Castello R. J Clin Endocrinol Metab. 2000 Jan;85(1):89-94.<\/p>\n\n\n\n

28-Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. Mackenzie IS, Macdonald TM, Thompson A, Morant S, Wei L. BMJ. 2012 Jul 13;345:e4447.<\/p>\n\n\n\n

29-Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. Mackenzie IS, Morant SV, Wei L, Thompson AM, MacDonald TM. Br J Clin Pharmacol. 2017 Mar;83(3):653-663.<\/p>\n\n\n\n

30-Spironolactone use and the risk of breast and gynecologic cancers. Biggar RJ, Andersen EW, Wohlfahrt J, Melbye M. Cancer Epidemiol. 2013 Dec;37(6):870-5.<\/p>\n\n\n\n

31-Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. Gilling-Smith C, Willis DS, Beard RW, Franks S. J Clin Endocrinol Metab. 1994 Oct;79(4):1158-65.<\/p>\n\n\n\n

32-Hyperinsulinemia amplifies GnRH agonist stimulated ovarian steroid secretion in women with polycystic ovary syndrome. Tosi F, Negri C, Perrone F, Dorizzi R, Castello R, Bonora E, Moghetti P. J Clin Endocrinol Metab. 2012 May;97(5):1712-9.<\/p>\n\n\n\n

33-Oestradiol feedback stimulation of androgen biosynthesis by human theca cells. Gilling-Smith C, Willis DS, Franks S. Hum Reprod. 1997 Aug;12(8):1621-8.<\/p>\n\n\n\n

34-Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review. Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS. J Clin Aesthet Dermatol. 2016 Jul;9(7):56-62.<\/p>\n\n\n\n

35-Androgen levels in adult females: changes with age, menopause, and oophorectomy. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. J Clin Endocrinol Metab. 2005 Jul;90(7):3847-53.<\/p>\n\n\n\n

36-Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Winters SJ, Talbott E, Guzick DS, Zborowski J, McHugh KP. Fertil Steril. 2000 Apr;73(4):724-9.<\/p>\n\n\n\n

37-Age-related differences in features associated with polycystic ovary syndrome in normogonadotrophic oligo-amenorrhoeic infertile women of reproductive years. Bili H, Laven J, Imani B, Eijkemans MJ, Fauser BC. Eur J Endocrinol. 2001 Dec;145(6):749-55.<\/p>\n\n\n\n

38-Long-term follow-up of patients with polycystic ovary syndrome: reproductive outcome and ovarian reserve. Hudecova M, Holte J, Olovsson M, Sundstr\u00f6m Poromaa I. Hum Reprod. 2009 May;24(5):1176-83.<\/p>\n\n\n\n

39-Hyperandrogenism in women with polycystic ovary syndrome persists after menopause. Markopoulos MC, Rizos D, Valsamakis G, Deligeoroglou E, Grigoriou O, Chrousos GP, Creatsas G, Mastorakos G. J Clin Endocrinol Metab. 2011 Mar;96(3):623-31.<\/p>\n\n\n\n

40-Clinical and biochemical presentation of polycystic ovary syndrome in women between the ages of 20 and 40. Liang SJ, Hsu CS, Tzeng CR, Chen CH, Hsu MI. Hum Reprod. 2011 Dec;26(12):3443-9.<\/p>\n\n\n\n

41-Ovarian age-related responsiveness to human chorionic gonadotropin in women with polycystic ovary syndrome. Piltonen T, Koivunen R, Perheentupa A, Morin-Papunen L, Ruokonen A, Tapanainen JS. J Clin Endocrinol Metab. 2004 Aug;89(8):3769-75.<\/p>\n\n\n\n

42-Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS. Puurunen J, Piltonen T, Morin-Papunen L, Perheentupa A, J\u00e4rvel\u00e4 I, Ruokonen A, Tapanainen JS. J Clin Endocrinol Metab. 2011 Jun;96(6):1827-34.43-Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. Mueller A, Gooren LJ, Naton-Sch\u00f6tz S, Cupisti S, Beckmann MW, Dittrich R. J Clin Endocrinol Metab. 2008 Apr;93(4):1408-11.<\/p>\n\n\n\n

44-Association between polycystic ovary syndrome and female-to-male transsexuality. Baba T, Endo T, Honnma H, Kitajima Y, Hayashi T, Ikeda H, Masumori N, Kamiya H, Moriwaka O, Saito T. Hum Reprod. 2007 Apr;22(4):1011-6.45-Prevalence of polycystic ovaries and polycystic ovary syndrome in lesbian women compared with heterosexual women. Agrawal R, Sharma S, Bekir J, Conway G, Bailey J, Balen AH, Prelevic G. Fertil Steril. 2004 Nov;82(5):1352-7.<\/p>\n\n\n\n

46-Endocrine evaluation of forty female-to-male transsexuals: increased frequency of polycystic ovarian disease in female transsexualism. Futterweit W, Weiss RA, Fagerstrom RM. Arch Sex Behav. 1986 Feb;15(1):69-78.<\/p>\n\n\n\n

47-The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, Kelestimur F, Macut D, Micic D, Pasquali R, Pfeifer M, Pignatelli D, Pugeat M, Yildiz BO; ESE PCOS Special Interest Group. Eur J Endocrinol. 2014 Oct;171(4):P1-29.<\/p>\n\n\n\n

48-Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. Moran LJ, Misso ML, Wild RA, Norman RJ. 2010 Jul-Aug;16(4):347-63.<\/p>\n\n\n\n

49-Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome. Carmina E, Bucchieri S, Mansueto P, Rini G, Ferin M, Lobo RA. Fertil Steril. 2009 Apr;91(4 Suppl):1332-5.<\/p>\n\n\n\n

50-Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Kirchengast S, Huber J. Hum Reprod. 2001 Jun;16(6):1255-60.<\/p>\n\n\n\n

51-Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. Carmina E, Bucchieri S, Esposito A, Del Puente A, Mansueto P, Orio F, Di Fede G, Rini G. J Clin Endocrinol Metab. 2007 Jul;92(7):2500-5.<\/p>\n\n\n\n

52-Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Goverde AJ, van Koert AJ, Eijkemans MJ, Knauff EA, Westerveld HE, Fauser BC, Broekmans FJ. Hum Reprod. 2009 Mar;24(3):710-7.<\/p>\n\n\n\n

53-Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Moran L, Teede H. Hum Reprod Update. 2009 Jul-Aug;15(4):477-88.<\/p>\n\n\n\n

54-Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. Legro RS, Kunselman AR, Dodson WC, Dunaif A.J Clin Endocrinol Metab. 1999 Jan;84(1):165-9.<\/p>\n\n\n\n

55-Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Diabetes Care. 1999 Jan;22(1):141-6.<\/p>\n\n\n\n

56-Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A. J Clin Endocrinol Metab. 2002 Mar;87(3):1017-23.<\/p>\n\n\n\n

57-Polycystic ovarian syndrome (PCOS): a significant contributor to the overall burden of type 2 diabetes in women. Talbott EO, Zborowski JV, Rager JR, Kip KE, Xu X, Orchard TJ.J Womens Health (Larchmt). 2007 Mar;16(2):191-7.<\/p>\n\n\n\n

58-Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Hum Reprod. 2001 Sep;16(9):1995-8.<\/p>\n\n\n\n

59-Glucose intolerance in a large cohort of mediterranean women with polycystic ovary syndrome: phenotype and associated factors. Gambineri A, Pelusi C, Manicardi E, Vicennati V, Cacciari M, Morselli-Labate AM, Pagotto U, Pasquali R. Diabetes. 2004 Sep;53(9):2353-8.<\/p>\n\n\n\n

60-Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, Haffner SM, Pettitt DJ, Sorkin JD, Muller DC, Collins VR, Hamman RF. Diabetes. 1997  Apr;46(4):701-10.<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Polikistik Over Sendromu\u2019nda cinsel iste\u011fi erkeklik hormonlar\u0131 (testosteron, dihidrotestosteron) ve \u00f6strojen (estradiol) hormonu belirlemektedir(5). Beyinde bulunan cinsel istek al\u0131c\u0131lar\u0131 (resept\u00f6r) testosteron taraf\u0131ndan uyar\u0131lmaktad\u0131r(6). 1-Polikistik Over Sendromu olan kad\u0131nlar\u0131n bir k\u0131sm\u0131nda erkeklik hormonlar\u0131 fazla miktarda \u00fcretilmektedir. Bir k\u0131sm\u0131nda ise erkeklik hormonu miktar\u0131 normal olmas\u0131na ra\u011fmen ba\u011flanarak onlar\u0131 etkisiz hale getiren madde olan Sex Hormone Binding Globulin (SHBG) daha […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-7974","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/pages\/7974","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/comments?post=7974"}],"version-history":[{"count":20,"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/pages\/7974\/revisions"}],"predecessor-version":[{"id":11184,"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/pages\/7974\/revisions\/11184"}],"wp:attachment":[{"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/media?parent=7974"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}